BOSTON and OKLAHOMA CITY , Oct. 9, 2024 /PRNewswire/ -- Wheeler Bio, an agile and boutique contract development and manufacturing organization (CDMO), today announced the appointment of Patrick Lucy as Chief Executive Officer. Patrick joins Wheeler with more than 32 years of extensive experience in the biotechnology industry.
As a seasoned senior executive, he has overseen numerous company milestones and driven significant growth. "We are thrilled to welcome Patrick to the Wheeler team," said Jesse McCool , Ph.D.
, Co-Founder and Chief Scientific Officer of Wheeler Bio. "His impressive track record of establishing and scaling biotechnology organizations make him the right leader to guide Wheeler as we transition to a fully integrated commercial-scale CDMO." Patrick most recently served as President and CEO of RoslinCT US (formerly Lykan Bioscience), a cell therapy contract manufacturer based in Hopkinton, Massachusetts , and Edinburgh, Scotland .
Under his leadership, he led the successful launch of the Lykan business and, just 19 months later, orchestrated its sale to GHO Capital, providing a successful exit for the original private equity investors. Following this acquisition, GHO integrated Lykan and RoslinCT under the RoslinCT name, further solidifying their market presence. "I am honored to join Wheeler Bio at such a pivotal time," said Patrick Lucy .
"Jesse and the entire Wheeler team have built a strong scientific foundation, and I am excited to lead Wheeler into the fu.